1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
01/19/2024 | MDRX | Buy Now | Veradigm | $8.35 | 31.74% | RBC Capital | Sean Dodge | $22 → $11 | Maintains | Outperform | Get Alert |
01/03/2024 | MDRX | Buy Now | Veradigm | $8.35 | 31.74% | Barclays | Stephanie Davis | → $11 | Initiates | → Equal-Weight | Get Alert |
11/14/2023 | MDRX | Buy Now | Veradigm | $8.35 | 55.69% | Stephens & Co. | Jeff Garro | → $13 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
10/10/2023 | MDRX | Buy Now | Veradigm | $8.35 | 55.69% | Stephens & Co. | Jeff Garro | → $13 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
07/06/2023 | MDRX | Buy Now | Veradigm | $8.35 | — | Argus Research | Jasper Hellweg | — | Downgrade | Buy → Hold | Get Alert |
04/12/2023 | MDRX | Buy Now | Veradigm | $8.35 | 55.69% | Stephens & Co. | Jeff Garro | → $13 | Initiates | → Equal-Weight | Get Alert |
02/01/2023 | MDRX | Buy Now | Veradigm | $8.35 | 121.56% | Piper Sandler | Jessica Tassan | $17 → $18.5 | Downgrade | Overweight → Neutral | Get Alert |
12/07/2022 | MDRX | Buy Now | Veradigm | $8.35 | 211.38% | Argus Research | Jasper Hellweg | → $26 | Upgrade | Hold → Buy | Get Alert |
11/18/2022 | MDRX | Buy Now | Veradigm | $8.35 | 139.52% | JP Morgan | Anne Samuel | $19 → $20 | Maintains | Underweight | Get Alert |
11/09/2022 | MDRX | Buy Now | Veradigm | $8.35 | 175.45% | Goldman Sachs | Cindy Motz | $22 → $23 | Upgrade | Neutral → Buy | Get Alert |
09/16/2022 | MDRX | Buy Now | Veradigm | $8.35 | — | Keybanc | Scott Schoenhaus | — | Initiates | → Sector Weight | Get Alert |
07/12/2022 | MDRX | Buy Now | Veradigm | $8.35 | 151.5% | Goldman Sachs | Cindy Motz | → $21 | Initiates | → Neutral | Get Alert |
06/10/2022 | MDRX | Buy Now | Veradigm | $8.35 | 103.59% | Piper Sandler | Jeff Garro | $19 → $17 | Maintains | Neutral | Get Alert |
05/06/2022 | MDRX | Buy Now | Veradigm | $8.35 | 127.54% | Piper Sandler | Jeff Garro | $22 → $19 | Maintains | Neutral | Get Alert |
03/18/2022 | MDRX | Buy Now | Veradigm | $8.35 | 163.47% | Piper Sandler | Jeff Garro | $19 → $22 | Maintains | Neutral | Get Alert |
03/04/2022 | MDRX | Buy Now | Veradigm | $8.35 | 211.38% | Deutsche Bank | George Hill | $20 → $26 | Upgrade | Hold → Buy | Get Alert |
03/03/2022 | MDRX | Buy Now | Veradigm | $8.35 | 187.43% | SVB Leerink | Stephanie Davis | $22 → $24 | Maintains | Outperform | Get Alert |
01/25/2022 | MDRX | Buy Now | Veradigm | $8.35 | 163.47% | SVB Leerink | Stephanie Davis | $19 → $22 | Upgrade | Market Perform → Outperform | Get Alert |
11/23/2021 | MDRX | Buy Now | Allscripts Healthcare | $8.35 | 139.52% | Deutsche Bank | George Hill | — | Maintains | Hold | Get Alert |
The latest price target for Veradigm (OTCEM: MDRX) was reported by RBC Capital on January 19, 2024. The analyst firm set a price target for $11.00 expecting MDRX to fall to within 12 months (a possible NaN% downside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Veradigm (OTCEM: MDRX) was provided by RBC Capital, and Veradigm maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veradigm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veradigm was filed on January 19, 2024 so you should expect the next rating to be made available sometime around January 19, 2025.
While ratings are subjective and will change, the latest Veradigm (MDRX) rating was a maintained with a price target of $22.00 to $11.00. The current price Veradigm (MDRX) is trading at is $undefined, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.